The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC. | COM | 00287Y109 | 2,018 | 32,000 | SH | SOLE | 32,000 | 0 | 0 | ||
| ADVAXIS INC | COM NEW | 007624208 | 6,413 | 600,000 | SH | SOLE | 600,000 | 0 | 0 | ||
| AEGERION PHARMACEUTICALS INC | COM | 00767E102 | 7,867 | 2,649,000 | SH | SOLE | 2,649,000 | 0 | 0 | ||
| APRICUS BIOSCIENCES INC | COM | 03832V109 | 4,898 | 14,479,052 | SH | SOLE | 14,479,052 | 0 | 0 | ||
| ARIAD PHARMACEUTICALS INC | COM | 04033A100 | 175,916 | 12,850,000 | SH | SOLE | 12,850,000 | 0 | 0 | ||
| ARRAY BIOPHARMA INC | COM | 04269X105 | 29,025 | 4,300,000 | SH | SOLE | 4,300,000 | 0 | 0 | ||
| AVEO PHARMACEUTICALS INC | COM | 053588109 | 1,780 | 2,000,000 | SH | SOLE | 2,000,000 | 0 | 0 | ||
| BIOGEN INC | COM | 09062X103 | 97,039 | 310,000 | SH | SOLE | 310,000 | 0 | 0 | ||
| INNOVIVA INC | COM | 45781M101 | 10,990 | 1,000,000 | SH | SOLE | 1,000,000 | 0 | 0 | ||
| INTRA CELLULAR THERAPIES INC | COM | 46116X101 | 10,286 | 675,000 | SH | SOLE | 675,000 | 0 | 0 | ||
| MEDICINES CO | COM | 584688105 | 66,120 | 1,752,000 | SH | SOLE | 1,752,000 | 0 | 0 | ||
| PACIRA PHARMACEUTICALS INC | COM | 695127100 | 14,714 | 430,000 | SH | SOLE | 430,000 | 0 | 0 | ||
| QUEST DIAGNOSTICS INC | COM | 74834L100 | 4,231 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| VIVUS INC | COM | 928551100 | 2,934 | 2,573,943 | SH | SOLE | 2,573,943 | 0 | 0 | ||